Small Pharma

Small Pharma is a neuropharmaceutical company focused on psychedelic-assisted therapies, specializing in the development of new treatments for mental health disorders led by intellectual property, with a focus on depression. In February 2021, Small Pharma launched a clinical program for DMT-assisted therapy. The program includes Phase I/IIa trials of the company's leading drug candidate and the development of a robust proprietary pipeline of preclinical assets.